{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:17:09Z","timestamp":1785453429885,"version":"3.56.0"},"reference-count":58,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"internal group funding"},{"name":"Government of Aragon"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Mycobacterium kansasii (Mkn) causes tuberculosis-like lung infection in both immunocompetent and immunocompromised patients. Current standard therapy against Mkn infection is lengthy and difficult to adhere to. Although \u03b2-lactams are the most important class of antibiotics, representing 65% of the global antibiotic market, they have been traditionally dismissed for the treatment of mycobacterial infections, as they were considered inactive against mycobacteria. A renewed interest in \u03b2-lactams as antimycobacterial agents has shown their activity against several mycobacterial species, including M. tuberculosis, M. ulcerans or M. abscessus; however, information against Mkn is lacking. In this study, we determined the in vitro activity of several \u03b2-lactams against Mkn. A selection of 32 agents including all \u03b2-lactam chemical classes (penicillins, cephalosporins, carbapenems and monobactams) with three \u03b2-lactamase inhibitors (clavulanate, tazobactam and avibactam) were evaluated against 22 Mkn strains by MIC assays. Penicillins plus clavulanate and first- and third-generation cephalosporins were the most active \u03b2-lactams against Mkn. Combinatorial time-kill assays revealed favorable interactions of amoxicillin\u2013clavulanate and cefadroxil with first-line Mkn treatment. Amoxicillin\u2013clavulanate and cefadroxil are oral medications that are readily available, and well tolerated with an excellent safety and pharmacokinetic profile that could constitute a promising alternative option for Mkn therapy.<\/jats:p>","DOI":"10.3390\/antibiotics12020335","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T03:34:30Z","timestamp":1675654470000},"page":"335","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Repurposing \u03b2-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Lara","family":"Mu\u00f1oz-Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-844X","authenticated-orcid":false,"given":"Jos\u00e9 A.","family":"A\u00ednsa","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain"},{"name":"CIBER Respiratory Diseases (CIBERES), Health Institute Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-0325","authenticated-orcid":false,"given":"Santiago","family":"Ram\u00f3n-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain"},{"name":"CIBER Respiratory Diseases (CIBERES), Health Institute Carlos III, 28029 Madrid, Spain"},{"name":"Research and Development Agency of Arag\u00f3n (ARAID) Foundation, 50018 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3389\/fmicb.2019.02918","article-title":"Genomic Insights Into the Mycobacterium kansasii Complex: An Update","volume":"10","author":"Jagielski","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rmed.2019.03.015","article-title":"Outcome of Patients with and Poor Prognostic Factors for Mycobacterium kansasii-Pulmonary Disease","volume":"151","author":"Liu","year":"2019","journal-title":"Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.3389\/fmicb.2018.02271","article-title":"Therapy for Mycobacterium kansasii Infection: Beyond 2018","volume":"9","author":"DeStefano","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.rmed.2019.01.012","article-title":"Treatment with a Macrolide-Containing Regimen for Mycobacterium kansasii Pulmonary Disease","volume":"148","author":"Moon","year":"2019","journal-title":"Respir. Med."},{"key":"ref_5","first-page":"653","article-title":"Nontuberculous Mycobacteria\u2014Overview","volume":"5","author":"Kohg","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_7","first-page":"977","article-title":"Pulmonary Disease by Non-Tuberculous Mycobacteria\u2013Clinical Management, Unmet Needs and Future Perspectives","volume":"11","author":"Larsson","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1002\/chem.201800923","article-title":"Synthesis of Avibactam Derivatives and Activity on \u03b2-Lactamases and Peptidoglycan Biosynthesis Enzymes of Mycobacteria","volume":"24","author":"Edoo","year":"2018","journal-title":"Chem. A Eur. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"34293","DOI":"10.1038\/srep34293","article-title":"Repurposing Clinically Approved Cephalosporins for Tuberculosis Therapy","volume":"6","author":"Villarejo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1128\/AAC.39.7.1454","article-title":"Susceptibilities of Nontuberculosis Mycobacterial Species to Amoxicillin-Clavulanic Acid Alone and in Combination with Antimycobacterial Agents","volume":"39","author":"Utrup","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","first-page":"1081","article-title":"Inhibition of \u03b2-Lactamases of Mycobacteria by Avibactam and Clavulanate","volume":"72","author":"Soroka","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial Susceptibility Testing, Drug Resistance Mechanisms, and Therapy of Infections with Nontuberculous Mycobacteria","volume":"25","author":"Nash","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00039-22","DOI":"10.1128\/msphere.00039-22","article-title":"Penicillin Binding Proteins and \u03b2-Lactamases of Mycobacterium tuberculosis: Reexamination of the Historical Paradigm","volume":"7","author":"Kumar","year":"2022","journal-title":"mSphere"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00790-22","DOI":"10.1128\/aac.00790-22","article-title":"Strongly Bactericidal All-Oral b-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease","volume":"66","author":"Negatu","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e02545-20","DOI":"10.1128\/AAC.02545-20","article-title":"\u03b2-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates","volume":"65","author":"Galanis","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1164\/rccm.202108-1976OC","article-title":"Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial","volume":"205","author":"Gupte","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1128\/AAC.05690-11","article-title":"Meropenem-Clavulanic Acid Shows Activity against Mycobacterium tuberculosis in Vivo","volume":"56","author":"England","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/iub.1875","article-title":"Have We Realized the Full Potential of \u03b2-Lactams for Treating Drug-Resistant TB?","volume":"70","author":"Lamichhane","year":"2018","journal-title":"IUBMB Life"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1128\/AAC.01063-15","article-title":"Combinations of \u03b2-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a Dhp-i-Deficient Mouse Model of Tuberculosis Infection","volume":"59","author":"Rullas","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1128\/AAC.03461-14","article-title":"Rapid Cytolysis of Mycobacterium tuberculosis by Faropenem, an Orally Bioavailable \u03b2-Lactam Antibiotic","volume":"59","author":"Dhar","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"G\u00f3mara M1, R.-G.S. (2019). The FICI Paradigm: Correcting Flaws in Antimicrobial in Vitro Synergy Screens at Their Inception. Biochem Pharmacol., 163, 299\u2013307.","DOI":"10.1016\/j.bcp.2019.03.001"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.jfma.2020.05.018","article-title":"Treatment of Pulmonary Disease Caused by Mycobacterium kansasii","volume":"119","author":"Huang","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1128\/AAC.45.11.3056-3058.2001","article-title":"Rifampin Resistance in Mycobacterium kansasii Is Associated with RpoB Mutations","volume":"45","author":"Klein","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1183\/09031936.00024008","article-title":"Long-Term Relapses after 12-Month Treatment for Mycobacterium kansasii Lung Disease","volume":"33","author":"Santin","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"684515","DOI":"10.3389\/fcimb.2021.684515","article-title":"Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing","volume":"11","author":"Boyd","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: A New Antibiotic Nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"Bush and Bradford-2016-\u03b2-Lactams and \u03b2-Lactamase Inhibitors An Overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three Decades of \u03b2-Lactamase Inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Story-Roller, E., Maggioncalda, E.C., and Lamichhane, G. (2019). Select -Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02613-18"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/jac\/dkx284","article-title":"Effect of \u03b2-Lactamase Production and \u03b2-Lactam Instability on MIC Testing Results for Mycobacterium abscessus","volume":"72","author":"Rominski","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0014-5793(97)00286-X","article-title":"Contribution of \u03b2-Lactamase Production to the Resistance of Mycobacteria to \u03b2-Lactam Antibiotics","volume":"406","author":"Quinting","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jac\/22.6.863","article-title":"In-Vitro Susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to Amoxycillin and Ticarcillin in Combination with Clavulanic Acid","volume":"22","author":"Wong","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2217\/fmb-2019-0318","article-title":"Tuberculosis and Beta-Lactam Antibiotics","volume":"15","author":"Gun","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s13063-022-06473-9","article-title":"Comparison of 8 Weeks Standard Treatment (Rifampicin plus Clarithromycin) vs. 4 Weeks Standard plus Amoxicillin\/Clavulanate Treatment [RC8 vs. RCA4] to Shorten Buruli Ulcer Disease Therapy (the BLMs4BU Trial): Study Protocol for a Randomized Controlled Multi-Centre Trial in Benin","volume":"23","author":"Johnson","year":"2022","journal-title":"Trials"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/cid\/ciab535","article-title":"\u201cOne-Two Punch\u201d: Synergistic \u00df-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes","volume":"73","author":"Nguyen","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.cmi.2020.07.036","article-title":"Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex Isolates\u2014The EUCAST Broth Microdilution Reference Method for MIC Determination","volume":"26","author":"Werngren","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_37","unstructured":"Woods, G.L. (2011). Clinical and Laboratory Standards Institute: Wayne, PA, U. Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes: Approved Standard, Clinical and Laboratory Standards Institute."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1128\/AAC.00598-15","article-title":"Hydrolysis of Clavulanate by Mycobacterium tuberculosis \u03b2-Lactamase BlaC Harboring a Canonical SDN Motif","volume":"59","author":"Soroka","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","first-page":"1051","article-title":"\u03b2-Lactamase Inhibition by Avibactam in Mycobacterium abscessus","volume":"70","author":"Bernut","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1128\/jcm.34.5.1321-1322.1996","article-title":"Stability of Amoxicillin-Clavulanate in BACTEC Medium Determined by High-Performance Liquid Chromatography and Bioassay","volume":"34","author":"Moore","year":"1996","journal-title":"J. Clin. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10408347.2016.1219649","article-title":"Characteristics, Properties and Analytical Methods of Cefadroxil: A Review","volume":"47","author":"Salgado","year":"2017","journal-title":"Crit. Rev. Anal. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jchromb.2016.06.033","article-title":"Simultaneous Determination and Stability Studies of Linezolid, Meropenem and Vancomycin in Bacterial Growth Medium by High-Performance Liquid Chromatography","volume":"1028","author":"Wicha","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0007126","DOI":"10.1371\/journal.pntd.0007126","article-title":"Triple Oral Beta-Lactam Containing Therapy for Buruli Ulcer Treatment Shortening","volume":"13","author":"Thompson","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/41.6.589","article-title":"Forty Years of \u03b2-Lactam Research","volume":"41","author":"Rolinson","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1086\/513945","article-title":"Activity of Amoxicillin\/Clavulanate in Patients with Tuberculosis","volume":"26","author":"Chambers","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/00365540152029954","article-title":"Early Bactericidal Activity of Amoxicillin in Combination with Clavulanic Acid in Patients with Sputum Smear-Positive Pulmonary Tuberculosis","volume":"33","author":"Donald","year":"2001","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJMc1513236","article-title":"\u03b2-Lactams against Tuberculosis\u2014New Trick for an Old Dog?","volume":"375","author":"Diacon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5588\/ijtld.11.0414","article-title":"Clinical Use of the Meropenem-Clavulanate Combination for Extensively Drug-Resistant Tuberculosis","volume":"16","author":"Payen","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkh050","article-title":"Augmentin\u00ae (Amoxicillin\/Clavulanate) in the Treatment of Community-Acquired Respiratory Tract Infection: A Review of the Continuing Development of an Antimicrobial Agent","volume":"53","author":"White","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/14787210.5.1.29","article-title":"Cefdinir: An Oral Cephalosporin for the Treatment of Respiratory Tract Infections and Skin and Skin Structure Infections","volume":"5","author":"Sader","year":"2007","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_51","first-page":"231","article-title":"Cefditoren Pivoxilo: Una Nueva Cefalosporina Oral Para Infecciones de V\u00edas Respiratorias y de Piel y Tejidos Blandos Cefditoren Pivoxil: A New Oral Cephalosporin for Skin, Soft Tissue and Respiratory Tract Infections","volume":"19","author":"Salavert","year":"2006","journal-title":"Rev Esp Quimioter."},{"key":"ref_52","first-page":"42","article-title":"Bioequivalence Study of Two Oral Formulations of Cefadroxil in Healthy Volunteers","volume":"58","author":"Porta","year":"2008","journal-title":"Arzneimittelforschung"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1164\/rccm.201807-1273PP","article-title":"Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections: A Road Map for Research","volume":"199","author":"Abate","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_54","first-page":"1","article-title":"Qualification Opinion: In Vitro Hollow Fiber System Model of Tuberculosis (HSF-TB)","volume":"44","author":"Department","year":"2015","journal-title":"Eur. Med. Agency"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41467-017-01929-y","article-title":"A General Pharmacodynamic Interaction Model Identifies Perpetrators and Victims in Drug Interactions","volume":"8","author":"Wicha","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/cpt.1814","article-title":"Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development","volume":"108","author":"Susanto","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1128\/jcm.31.2.175-178.1993","article-title":"Rapid Identification of Mycobacteria to the Species Level by Polymerase Chain Reaction and Restriction Enzyme Analysis","volume":"31","author":"Telenti","year":"1993","journal-title":"J. Clin. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Mu\u00f1oz, L., Shoen, C., Sweet, G., Vitoria, A., Bull, T.J., Cynamon, M., Thompson, C.J., and Ram\u00f3n-Garc\u00eda, S. (2021). Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040381"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/335\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:24:58Z","timestamp":1760120698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,5]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["antibiotics12020335"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12020335","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,5]]}}}